Literature DB >> 26988990

Intracrine VEGF Signaling Mediates the Activity of Prosurvival Pathways in Human Colorectal Cancer Cells.

Rajat Bhattacharya1, Xiang-Cang Ye1, Rui Wang1, Xia Ling1, Madonna McManus2, Fan Fan1, Delphine Boulbes1, Lee M Ellis3.   

Abstract

The effects of vascular endothelial growth factor-A (VEGF-A/VEGF) and its receptors on endothelial cells function have been studied extensively, but their effects on tumor cells are less well defined. Studies of human colorectal cancer cells where the VEGF gene has been deleted suggest an intracellular role of VEGF as a cell survival factor. In this study, we investigated the role of intracrine VEGF signaling in colorectal cancer cell survival. In human colorectal cancer cells, RNAi-mediated depletion of VEGF decreased cell survival and enhanced sensitivity to chemotherapy. Unbiased reverse phase protein array studies and subsequent validation experiments indicated that impaired cell survival was a consequence of disrupted AKT and ERK1/2 (MAPK3/1) signaling, as evidenced by reduced phosphorylation. Inhibition of paracrine or autocrine VEGF signaling had no effect on phospho-AKT or phospho-ERK1/2 levels, indicating that VEGF mediates cell survival via an intracellular mechanism. Notably, RNAi-mediated depletion of VEGF receptor VEGFR1/FLT1 replicated the effects of VEGF depletion on phospho-AKT and phospho-ERK1/2 levels. Together, these studies show how VEGF functions as an intracrine survival factor in colorectal cancer cells, demonstrating its distinct role in colorectal cancer cell survival. Cancer Res; 76(10); 3014-24. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26988990      PMCID: PMC4873444          DOI: 10.1158/0008-5472.CAN-15-1605

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  44 in total

Review 1.  Tumor angiogenesis: molecular pathways and therapeutic targets.

Authors:  Sara M Weis; David A Cheresh
Journal:  Nat Med       Date:  2011-11-07       Impact factor: 53.440

Review 2.  Reappraising antiangiogenic therapy for breast cancer.

Authors:  Robert S Kerbel
Journal:  Breast       Date:  2011-10       Impact factor: 4.380

3.  VEGFR-1 Pseudogene Expression and Regulatory Function in Human Colorectal Cancer Cells.

Authors:  Xiangcang Ye; Fan Fan; Rajat Bhattacharya; Seth Bellister; Delphine R Boulbes; Rui Wang; Ling Xia; Cristina Ivan; Xiaofeng Zheng; George A Calin; Jing Wang; Xiongbin Lu; Lee M Ellis
Journal:  Mol Cancer Res       Date:  2015-06-03       Impact factor: 5.852

4.  Hypoxia-inducible factor-1alpha promotes nonhypoxia-mediated proliferation in colon cancer cells and xenografts.

Authors:  Duyen T Dang; Fang Chen; Lawrence B Gardner; Jordan M Cummins; Carlo Rago; Fred Bunz; Sergey V Kantsevoy; Long H Dang
Journal:  Cancer Res       Date:  2006-02-01       Impact factor: 12.701

5.  VEGF(165) promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition.

Authors:  Sergio Dias; Sergey V Shmelkov; George Lam; Shahin Rafii
Journal:  Blood       Date:  2002-04-01       Impact factor: 22.113

Review 6.  The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions.

Authors:  Hiroyuki Takahashi; Masabumi Shibuya
Journal:  Clin Sci (Lond)       Date:  2005-09       Impact factor: 6.124

7.  Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

Authors:  Leonard B Saltz; Stephen Clarke; Eduardo Díaz-Rubio; Werner Scheithauer; Arie Figer; Ralph Wong; Sheryl Koski; Mikhail Lichinitser; Tsai-Shen Yang; Fernando Rivera; Felix Couture; Florin Sirzén; Jim Cassidy
Journal:  J Clin Oncol       Date:  2008-04-20       Impact factor: 44.544

Review 8.  Pathways mediating resistance to vascular endothelial growth factor-targeted therapy.

Authors:  Lee M Ellis; Daniel J Hicklin
Journal:  Clin Cancer Res       Date:  2008-10-15       Impact factor: 12.531

9.  Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity.

Authors:  Rakesh Kumar; Victoria B Knick; Sharon K Rudolph; Jennifer H Johnson; Renae M Crosby; Ming-Chih Crouthamel; Teresa M Hopper; Charles G Miller; Laura E Harrington; James A Onori; Robert J Mullin; Tona M Gilmer; Anne T Truesdale; Andrea H Epperly; Amogh Boloor; Jeffrey A Stafford; Deirdre K Luttrell; Mui Cheung
Journal:  Mol Cancer Ther       Date:  2007-07       Impact factor: 6.261

10.  Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.

Authors:  John M L Ebos; Christina R Lee; William Cruz-Munoz; Georg A Bjarnason; James G Christensen; Robert S Kerbel
Journal:  Cancer Cell       Date:  2009-03-03       Impact factor: 31.743

View more
  23 in total

1.  VEGF-R1 as a Potential Molecular Target for Anticancer Therapy.

Authors:  E G Tyrsina; S I Nikulitskiy; A N Inshakov; O O Ryabaya
Journal:  Dokl Biochem Biophys       Date:  2018-03-14       Impact factor: 0.788

2.  High PGD2 receptor 2 levels are associated with poor prognosis in colorectal cancer patients and induce VEGF expression in colon cancer cells and migration in a zebrafish xenograft model.

Authors:  Pujarini Dash; Souvik Ghatak; Geriolda Topi; Shakti Ranjan Satapathy; Fredrik Ek; Karin Hellman; Roger Olsson; Lubna M Mehdawi; Anita Sjölander
Journal:  Br J Cancer       Date:  2021-11-08       Impact factor: 9.075

3.  Functional genetic screen identifies ITPR3/calcium/RELB axis as a driver of colorectal cancer metastatic liver colonization.

Authors:  Ryan H Moy; Alexander Nguyen; Jia Min Loo; Norihiro Yamaguchi; Christina M Kajba; Balaji Santhanam; Benjamin N Ostendorf; Y Gloria Wu; Saeed Tavazoie; Sohail F Tavazoie
Journal:  Dev Cell       Date:  2022-04-28       Impact factor: 13.417

4.  Fms related tyrosine kinase 1 (Flt1) functions as an oncogene and regulates glioblastoma cell metastasis by regulating sonic hedgehog signaling.

Authors:  Kun Jiang; Yan-Ping Wang; Xiao-Dong Wang; Xiao-Bo Hui; Lian-Shu Ding; Ji Liu; Dai Liu
Journal:  Am J Cancer Res       Date:  2017-05-01       Impact factor: 6.166

5.  Intracrine VEGF signalling mediates colorectal cancer cell migration and invasion.

Authors:  Rajat Bhattacharya; Fan Fan; Rui Wang; Xiangcang Ye; Ling Xia; Delphine Boulbes; Lee M Ellis
Journal:  Br J Cancer       Date:  2017-07-25       Impact factor: 7.640

6.  Glioblastoma stem-like cells secrete the pro-angiogenic VEGF-A factor in extracellular vesicles.

Authors:  Lucas Treps; Raul Perret; Sébastien Edmond; Damien Ricard; Julie Gavard
Journal:  J Extracell Vesicles       Date:  2017-08-08

7.  Dioscin induces prostate cancer cell apoptosis through activation of estrogen receptor-β.

Authors:  Xufeng Tao; Lina Xu; Lianhong Yin; Xu Han; Yan Qi; Youwei Xu; Shasha Song; Yanyan Zhao; Jinyong Peng
Journal:  Cell Death Dis       Date:  2017-08-10       Impact factor: 8.469

8.  Elevated Gab2 induces tumor growth and angiogenesis in colorectal cancer through upregulating VEGF levels.

Authors:  Chenbo Ding; Junmin Luo; Xiaobo Fan; Longmei Li; Shanshan Li; Kunming Wen; Jihong Feng; Guoqiu Wu
Journal:  J Exp Clin Cancer Res       Date:  2017-04-18

9.  Anti-tumour activity of tivozanib, a pan-inhibitor of VEGF receptors, in therapy-resistant ovarian carcinoma cells.

Authors:  Majid Momeny; Zahra Sabourinejad; Ghazaleh Zarrinrad; Farima Moghaddaskho; Haniyeh Eyvani; Hassan Yousefi; Shahab Mirshahvaladi; Ensieh M Poursani; Farinaz Barghi; Arash Poursheikhani; Leila Dardaei; Davood Bashash; Mahmoud Ghazi-Khansari; Seyyed M Tavangar; Ahmad R Dehpour; Marjan Yaghmaie; Kamran Alimoghaddam; Ardeshir Ghavamzadeh; Seyed H Ghaffari
Journal:  Sci Rep       Date:  2017-04-06       Impact factor: 4.379

10.  NOP14 regulates the growth, migration, and invasion of colorectal cancer cells by modulating the NRIP1/GSK-3β/β-catenin signaling pathway.

Authors:  Xuanjin Zhu; Weilu Jia; Yong Yan; Yong Huang; Bailin Wang
Journal:  Eur J Histochem       Date:  2021-07-02       Impact factor: 3.188

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.